Pharmacology and Clinical Drug Candidates in Redox Medicine

Area of Science:

• Biochemistry
• Pharmacology
• Pathophysiology

Background:

• Oxidative stress is implicated in numerous human diseases, but direct scavenging of pro-oxidant molecules has proven pharmacotherapeutically unsuccessful.
• Emerging strategies focus on targeting enzymatic sources of oxidative stress, with several enzymes linked to various pathologies.
• Drug development for these targets ranges from early-stage research to clinical application, including repurposing existing drugs.

Purpose of the Study:

• To explore the potential of targeting enzymatic sources of oxidative stress for therapeutic benefit.
• To review the current landscape of drug development for oxidative stress-related enzymes.
• To identify critical issues and future directions for translating research into clinical practice.

Main Methods:

• Review of current literature on oxidative stress, enzymatic targets, and pharmacological interventions.
• Analysis of the status of drug development for identified enzymes.
• Assessment of challenges in preclinical validation and drugability.

Main Results:

• While some targets have advanced pharmacology, many require optimized compounds and pharmacokinetic profiles.
• Inhibition of these enzymes may lead to unknown physiological functions and potential side effects.
• Current progress relies heavily on academic research, with opportunities for drug repurposing.

Conclusions:

• Targeting enzymatic sources of oxidative stress represents a significant therapeutic opportunity.
• Optimized compounds and collaborative efforts between academia and industry are crucial for clinical translation.
• Successful validation could lead to a new era of redox medicine, addressing a wide range of disorders.